Shot of Good News for This Vaccine Maker
Brandy is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
The Centers for Disease Control recently released a study showing that the introduction of human papillomavirus vaccines has significantly reduced infection rates among teenaged girls. That’s good news for the manufacturers of the only two HPV vaccines approved in the United States: Merck’s (NYSE: MRK) Gardasil and GlaxoSmithKline’s (NYSE: GSK) Cervarix.
The global HPV vaccine market has recently swayed towards one of these companies -- but what does that mean for its financial health?
HPV is an extremely common sexually transmitted disease. There are numerous types of HPV and many simply work themselves out of the body without symptoms. But other types can cause genital warts or cancer.
The new study was purposefully zoomed in on the types of HPV covered under the vaccines. There are over a dozen types of high risk HPV that can cause some form of cancer. Two types --16 and 18 - cause more than 70% of all cervical cancer cases. And those are the types that both Gardasil and Cervarix cover.
The study showed a 56% decrease in infection rates for those two types of HPV in teenaged females between the ages of 14 and 19 -- historically the target patient group for the vaccines. That’s a significant drop considering Gardasil didn’t hit the U.S. market until 2006.
And the reduction happened despite relatively poor adherence to the vaccine regimen, which requires a trio of injections. According to USA Today, 46% of young women receiving the vaccine stop at the first dose and only 32% finished the process.
The United States has a lower rate of HPV vaccinations than other countries such as Japan and Australia, which have stronger enrollment programs. But the evidence of how well the vaccines are working could send more patients to the doctor for vaccination.
Merck would see the most gains from an influx of vaccination patients. Gardasil is approved for two more HPV types than Cervarix. And Gardasil received Food and Drug Administration approval for vaccinating men against HPV to help protect against various types of cancer including anal and penile.
Gardasil’s sales grew 35% last year to $1.6 billion while Cervarix sales fell 46% to around $412 million. Cervarix will continue to fall without broader indications -- especially now that the U.K.’s National Health Service has switched its official recommendation from Cervarix to Gardasil. And both drugs could suffer if Japan’s current investigation into the safety issues of the vaccines turns out to be anything other than caution.
So Merck's winning the vaccine race. But how dependent are the companies on having a successful product in this space?
Merck's limping after the patent expiration of Singulair, the $4 billion asthma and allergy medication. Without Singulair, Gardasil becomes Merck's fourth best-selling drug. The company's product portfolio is a bit hit-and-miss and an established growth opportunity can go a long way in promoting investor confidence.
The Cervarix decline comes at an inopportune time for GlaxoSmithKline. European austerity measures impacted overall sales last year and the year-over-year drop in Cervarix demand hit in the third quarter. Share prices down over 9% for 2012.
But investors have had time to cope with the slump in Cervarix sales. Attention is instead focused on the late-stage pipeline, which will serve as the real make-or-break issue for GlaxoSmithKline this year.
Foolish final thoughts
Even though the CDC’s study had a narrow focus, the results show that the vaccines are helping to keep dangerous forms of HPV in check. The U.S. needs to increase the number of vaccinated people and this new data might be enough to get some doubtful patients off the fence. And an influx of patients could move Gardasil up the ranks of Merck's products -- and make the company a safer bet after the Singulair loss.
Obamacare will undoubtedly have far-reaching effects. The Motley Fool’s new free report, “Everything You Need to Know About Obamacare,” lets you know how your health insurance, your taxes, and your portfolio could be impacted. Click here to read more.
Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!